People: Repligen Corp (RGEN.O)

RGEN.O on Nasdaq

36.65USD
28 Jul 2015
Change (% chg)

$0.55 (+1.52%)
Prev Close
$36.10
Open
$36.41
Day's High
$37.34
Day's Low
$35.64
Volume
375,397
Avg. Vol
386,658
52-wk High
$42.48
52-wk Low
$18.23

Search Stocks

Goldberg, Alfred 

Dr. Alfred Lewis Goldberg, Ph.D., is Independent Director of Repligen Corp., since July 1, 2008. Mr. Goldberg is currently a Professor of Cell Biology at Harvard Medical School. Mr. Goldberg has been associated with Harvard University during his entire academic career. He was appointed an Assistant Professor of Physiology at Harvard Medical School in 1969 and has been a full professor since 1977. Mr. Goldberg has served as a consultant to many biotechnology and pharmaceutical companies and served on Scientific Advisory Boards of numerous foundations and biotechnology companies (including Biogen, ArQule, Elan and ProScript). Mr. Goldberg earned an A.B. from Harvard College in 1963, was a Churchill Scholar at Cambridge University and after studying at Harvard Medical School, earned his Ph.D. from Harvard University in 1968. He is internationally recognized for his multiple discoveries relating to protein degradation in cells and especially relating to the physiological functions and mechanisms of the ubiquitin-proteasome pathway. These discoveries provided the basis for the development of proteasome inhibitors which are widely used in cancer treatment. Mr. Goldberg is a member of the Institute of Medicine of the National Academy of Sciences and American Academy of Arts and Sciences.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Awards, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Karen Dawes

--

Alexander Rich

--

Tony Hunt

1,205,620

Jon Snodgres

484,774

James Rusche

654,351

Howard Benjamin

587,391
As Of  30 Dec 2014
Search Stocks